Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and amaleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402. In Vitro Antibody-drug conjugates deliver anticancer agents selectively and efficiently to tumor tissue and have significant antitumor efficacy with a wide therapeutic window. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:Camptothecins